Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

690 - Paclitaxel every-3-weeks versus weekly Paclitaxel and versus weekly Vinorelbine in Metastatic Breast Cancer


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Breast Cancer


Lika Katselashvili


Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365


L. Katselashvili1, I. Kiladze1, M. Katcharava1, N. Jokhadze1, T. Melkadze2, A. Matitashvili3, M. Zhvania4, N. Sharikadze5, F. Todua6

Author affiliations

  • 1 Oncology, Research Institute of Clinical Medicine, 0112 - Tbilisi/GE
  • 2 Medical Oncology, Research Institute of Clinical Medicine, 0112 - Tbilisi/GE
  • 3 Oncology, Mardaleishvili Medical Centre, 0186 - Tbilisi/GE
  • 4 Oncology, Conssillium Medulla, 0186 - Tbilisi/GE
  • 5 Medical Oncology, MediclubGeorgia, 0160 - Tbilisi/GE
  • 6 Radiology, Research Institute of Clinical Medicine, 0112 - Tbilisi/GE


Abstract 690


Single-agent chemotherapy (CT) is widely used in the management of HER2-negative breast cancer patients (pts). As both Paclitaxel (P) and Vinorelbine (V) have demonstrated efficacy in the treatment of Metastatic Breast Cancer (MBC), they are recommended among the standard available CT agents for MBC patients. This study compares the efficacy and safety profile of most frequently used three treatment regimens: Paclitaxel every-3-weeks (3-w-P) versus weekly Paclitaxel(w-P) and versus weekly Vinorelbine (w-V) in MBC. Primary objective: Time to progression (TTP). Secondary objectives: evaluation of safety profiles, clinical benefit and response rate (RR) of all arms.


In this open-label randomized prospective study, pts were randomized (2:2:1) to receive either: intravenously 3-w-P every 21 days, w-P 80 mg/m2/week (day 1, 8, 15) every 28 days or w-V 25 mg/m2/week (day 1, 8, 15) every 28 days. Main eligibility criteria: age ≥18 years, documented metastatic disease previously untreated by CT for metastatic setting, ER/PR positive and HER2-negative disease, or triple negative disease. ECOG≤2.


From April 2014 to April 2015, 95 pts were included. 39 received 3-w-P; 38 received w-P and 18 received w-V per protocol. Median age was 58 years (range 38-79), median duration of treatment 11.5 weeks (range 9-24). Efficacy: with a median follow up of 24 months (m), median time to progression (primary endpoint) was 10.3m, 9.8m and 9.6m in 3-w-P arm, w-P and in w-V arm respectively (p = 0.006). Safety: w-V was much better tolerated with fewer G 3/4 toxicity events (n = 2) than w-P and 3-w-P (n = 23 and 16). Neuropathy G3/4 was mostly reported in 3-w-P and w-P arm than in V arm (75% vs. 69% vs. 17%). G3/4 alopecia was reported in both P arms (94%) when in V arm G3 alopecia was only in 6% of pts.


Weekly Paclitaxel appeared as effective as every-3-weekly regimen and weekly Vinorelbine, however neurotoxicity is a treatment-limiting toxicity for both Paclitaxel regimen. Vinorelbine had fewer significant grade 3-4 toxicities than both Paclitaxel arms and had better RR. Larger randomised studies are needed to determine the efficacy and overall survival of Paclitaxel versus Vinorelbine.

Clinical trial identification

Legal entity responsible for the study

Lika Katselashvili




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.